We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Fig 4.

Fig 4. From: Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges.

MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial design.

Sumithra J. Mandrekar, et al. J Clin Oncol. 2009 August 20;27(24):4027-4034.
2.
Fig 3.

Fig 3. From: Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges.

TAILORx (Trial Assigning Individualized Options for Treatment) trial design. RS, risk score.

Sumithra J. Mandrekar, et al. J Clin Oncol. 2009 August 20;27(24):4027-4034.
3.
Fig 2.

Fig 2. From: Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges.

ECOG (Eastern Cooperative Oncology Group) 5202 trial design. Cycle of treatment, 2 days every 2 weeks, repeat for 12 cycles.

Sumithra J. Mandrekar, et al. J Clin Oncol. 2009 August 20;27(24):4027-4034.
4.
Fig 1.

Fig 1. From: Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges.

MARVEL (Marker Validation for Erlotinib in Lung Cancer) trial design. Each cycle of treatment is 21 days. Stratification factors: ECOG performance status, gender, smoking status, histology, best response to prior chemotherapy. EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridization.

Sumithra J. Mandrekar, et al. J Clin Oncol. 2009 August 20;27(24):4027-4034.

Supplemental Content

Recent activity

Your browsing activity is temporarily unavailable.

Write to the Help Desk